When to Use IXEMPRA

When to use non-taxane therapy for metastatic breast cancer

Think IXEMPRA® (ixabepilone) when resistance emerges in mBC

When resistance emerges in the adjuvant setting1

  • Consider IXEMPRA + capecitabine in patients resistant to an anthracycline (progressing while on therapy or within 6 months) and a taxane (progressing while on therapy or within 12 months)

When resistance emerges in the metastatic setting1

  • Consider IXEMPRA + capecitabine in patients who are resistant to an anthracycline (progressing within 3 months) or in whom further anthracycline use is contraindicated and who progress within 4 months of taxane therapy
  • Consider IXEMPRA as monotherapy in patients resistant or refractory to an anthracycline, a taxane, and capecitabine

IXEMPRA, in combination with capecitabine, is the only FDA-approved, non-taxane microtubule-targeting agent indicated as first-line therapy for the treatment of patients with metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane1,2

References: 1. IXEMPRA (ixabepilone) Prescribing Information; January 2016. 2. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8(8):2086-2095. 

Indications and Important Safety Informationexpand

Important Safety Information
WARNING: Toxicity in hepatic impairment

Contraindications

Peripheral neuropathy

Myelosuppression

Hypersensitivity reaction

Pregnancy

Cardiac adverse reactions

Potential for cognitive impairment from excipients

Adverse reactions

Monotherapy

Combination with capecitabine

Cremophor is a registered trademark of BASF AG.

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN = upper limit of normal; CTC = common terminology criteria.

Indications

IXEMPRA® (ixabepilone) is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

  • Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting
  • Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting

IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

Please see US Full Prescribing Information, including boxed WARNING regarding hepatic impairment.

Medical information

For product information or to report an adverse reaction, please call 1-888-493-6772 or e-mail DrugSafety@propharmagroup.com.

This site is intended for US healthcare professionals.

The R-Pharm US Access and Support logo is a trademark and IXEMPRA® is a registered trademark of R-Pharm US Operating LLC, a wholly owned subsidiary of R-Pharm US LLC.

© 2021, R-PHARM US. All rights reserved. IXE-00096-02   08/16

Please verify if you are a US healthcare professional